

Attorney Docket No. Patent Application entitled: "Protracted GLP-1

Applicants:

Compositions" Jensen et al. 09/767,981

USSN:

The USPTO hereby acknowledges receipt of the

1. Certificate of Mailing

2. Petition and Fee for Extension of Time (in duplicate)

Amendment and Response

Sequence Listing

Copy of Notice to Comply with Requirements for Patent Applications with Nucleotide Sequence Disk Containing Sequence Listing

RBOR/RHAJ January 15, 2003

VIA First Class Mail

JAN 2 9 REC'D

Attorney Docket No. Patent Application entitled: Protracted GLP-1

4343.214-US Compositions" Jensen et al. 09/767,981

Applicants:

The USPTO hereby acknowledges receipt of the following:

1. Certificate of Mailing

Petition and Fee for Extension of Time (in duplicate)

Amendment and Response

Americanient and Response
Sequence Listing
Copy of Notice to Comply with Requirements for
Patent Applications with Nucleotide Sequence

Disk Containing Sequence Listing

RBOR/RHAJ January 15, 2003

VIA First Class Mail

Pull to Open --

naq0 of Iluq ---

DISK MAILER Tenson et al.

Title: Protracted GLP-1

Compositions

Sereal No: 29/767, 981


Docket No: 4343 214-US

Version 3.2 Patent-In

Captuare

Do not bend or fold Avoid exposure to all magnetic fields

> Inventor Tensen et at Title Probacted 6:11-11 Compositions Sexual No 09/767,981 Versicon Patent-In 3.2 Dodeet No 4343 214-VS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of: Jensen et al.

Serial No.: 09/767.981

Group Art Unit: 1647

Filed: January 23, 2001

Examiner: David Romeo

Confirmation No. 2751

For: Protracted GLP-1 Compositions

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Amendment and Response
- 2. Petition and Fee for Extension of Time (in duplicate)
- 3. Sequence Listing
- 4. Copy of Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence
- 5. Disk Containing Sequence Listing

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents Washington, DC 20231

on January 15, 2003.

Rashida Haji

(name of person mailing paper)

(signature of person mailing paper)

Mailing Address: Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800